FDMT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FDMT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
4D Molecular Therapeutics's book value per share for the quarter that ended in Mar. 2024 was $11.74.
During the past 12 months, 4D Molecular Therapeutics's average Book Value Per Share Growth Rate was 78.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -9.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of 4D Molecular Therapeutics was -9.40% per year. The lowest was -9.40% per year. And the median was -9.40% per year.
4D Molecular Therapeutics's current price is $25.15. Its book value per share for the quarter that ended in Mar. 2024 was $11.74. Hence, today's PB Ratio of 4D Molecular Therapeutics is 2.14.
During the past 7 years, the highest P/B Ratio of 4D Molecular Therapeutics was 14.58. The lowest was 0.69. And the median was 2.61.
The historical data trend for 4D Molecular Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4D Molecular Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Book Value per Share | Get a 7-Day Free Trial | -4.92 | 9.61 | 9.90 | 7.09 | 7.15 |
4D Molecular Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Book Value per Share | Get a 7-Day Free Trial | 6.58 | 7.74 | 7.72 | 7.15 | 11.74 |
For the Biotechnology subindustry, 4D Molecular Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where 4D Molecular Therapeutics's PB Ratio falls into.
4D Molecular Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (307.83 | - | 0.00) | / | 43.08 | |
= | 7.15 |
4D Molecular Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (600.56 | - | 0.00) | / | 51.16 | |
= | 11.74 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
4D Molecular Therapeutics (NAS:FDMT) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of 4D Molecular Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
David Kirn | director, officer: Chief Executive Officer | C/O 4D MOLECULAR THERAPEUTICS INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Uneek Mehra | officer: See Remarks | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Rose Sharon Shabet | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Opportunities Parent Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Ole Andreas Halvorsen | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
David C. Ott | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Opportunities Portfolio Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Opportunities Gp Llc | 10 percent owner | 55 RAILROAD AVENUE, GREENWICH CT 06830 |
Viking Global Opportunities Illiquid Investments Sub-master Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Jacob Chacko | director | C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121 |
Scott Bizily | officer: Chief Legal and HR Officer | C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608 |
Robert Young Kim | officer: Chief Medical Officer | C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608 |
Noriyuki Kasahara | director | C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608 |
Bvf I Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
From GuruFocus
By sperokesalga sperokesalga • 06-07-2023
By GuruFocus Research • 01-06-2024
By sperokesalga sperokesalga • 02-16-2023
By sperokesalga sperokesalga • 05-24-2023
By Marketwired • 08-09-2023
By Marketwired • 09-07-2023
By Marketwired • 10-23-2023
By sperokesalga sperokesalga • 04-13-2023
By sperokesalga sperokesalga • 05-04-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.